Utilizing Ras signaling pathway to direct selective replication of herpes simplex virus-1

PLoS ONE

Volumn 4, Issue 8, 2009, Pages

  Pan, Weihong ^a   Bodempudi, Vidya ^a   Esfandyari, Tuba ^b   Farassati, Faris ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFECTED CELL PROTEIN 4; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN C; RAS PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ELK; UNCLASSIFIED DRUG; VIRUS PROTEIN; PROTEIN P21;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INVASION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL DEATH; COLONY FORMATION; CONTROLLED STUDY; ENZYME ACTIVATION; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; VERO CELL; VIRUS CELL INTERACTION; VIRUS MUTANT; VIRUS REPLICATION; CELL CYCLE; CELL DIVISION; CELL LINE; ENZYMOLOGY; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

HERPES; HERPESVIRIDAE; HUMAN HERPESVIRUS 1;

CELL CYCLE; CELL DIVISION; CELL LINE; CELL LINE, TUMOR; ENZYME ACTIVATION; HERPESVIRUS 1, HUMAN; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS P21(RAS); SIGNAL TRANSDUCTION; VIRUS REPLICATION;

EID: 68349144521     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0006514     Document Type: Article

References (28)

1. Sundaram MV (2006) RTK/Ras/MAPK signaling. WormBook. pp 1-19.
2. Molina JR, Adjei AA (2006) The Ras/Raf/MAPK pathway. J Thorac Oncol 1: 7-9.
3. Buday L, Downward J (2008) Many faces of Ras activation. Biochim Biophys Acta.
4. Lawrence MC, Jivan A, Shao C, Duan L, Goad D, et al. (2008) The roles of MAPKs in disease. Cell Res 18: 436-442.
5. Alvarado Y, Giles FJ (2007) Ras as a therapeutic target in hematologic malignancies. Expert Opin Emerg Drugs 12: 271-284.
6. Chambard JC, Lefloch R, Pouyssegur J, Lenormand P (2007) ERK implication in cell cycle regulation. Biochim Biophys Acta 1773: 1299-1310.
7. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, et al. (2007) Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773: 1263-1284.
8. Meloche S, Pouyssegur J (2007) The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene 26: 3227-3239.
9. Roberts PJ, Der CJ (2007) Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26: 3291-3310.
10. Murphy LO, Blenis J (2006) MAPK signal specificity: the right place at the right time. Trends Biochem Sci 31: 268-275.
11. Shelton JG, Steelman LS, Lee JT, Knapp SL, Blalock WL, et al. (2003) Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cells. Oncogene 22: 2478-2492.
12. Zebisch A, Czernilofsky AP, Keri G, Smigelskaite J, Sill H, et al. (2007) Signaling through RAS-RAF-MEK-ERK: from basics to bedside. Curr Med Chem 14: 601-623.
13. Davis RJ (1995) Transcriptional regulation by MAP kinases. Mol ReprodDev 42: 459-467.
14. Kyosseva SV (2004) Mitogen-activated protein kinase signaling. Int Rev Neurobiol 59: 201-220.
15. Whitmarsh AJ, Shore P, Sharrocks AD, Davis RJ (1995) Integration of MAP kinase signal transduction pathways at the serum response element. Science 269: 403-407.
16. Cruzalegui FH, Cano E, Treisman R (1999) ERK activation induces phosphorylation of Elk-1 at multiple S/T-P motifs to high stoichiometry. Oncogene 18: 7948-7957.
17. Farassati F, Lee PW (2003) Ras signalling pathway: a gateway for HSV-1 infection. ScientificWorldJournal 3: 533-535.
18. Farassati F, Yang AD, Lee PW (2001) Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nat Cell Biol 3: 745-750.
19. Lee CY, Bu LX, Rennie PS, Jia WW (2007) An HSV-1 amplicon system for prostate-specific expression of ICP4 to complement oncolytic viral replication for in vitro and in vivo treatment of prostate cancer cells. Cancer Gene Ther 14: 652-660.
20. Moira Brown S, RM A (1998) Herpes Simplex Virus Protocols (Methods in Molecular Medicine).
21. White CM, Heidenreich O, Nordheim A, Beerman TA (2000) Evaluation of the effectiveness of DNA-binding drugs to inhibit transcription using the c-fos serum response element as a target. Biochemistry 39: 12262-12273.
22. Coleman ML, Marshall CJ, Olson MF (2004) RAS and RHO GTPases in G1-phase cell-cycle regulation. Nat Rev Mol Cell Biol 5: 355-366.
23. Song B, Liu JJ, Yeh KC, Knipe DM (2000) Herpes simplex virus infection blocks events in the G1 phase of the cell cycle. Virology 267: 326-334.
24. Song B, Yeh KC, Liu J, Knipe DM (2001) Herpes simplex virus gene products required for viral inhibition of expression of G1-phase functions. Virology 290: 320-328.
25. Ricote M, Garcia-Tunon I, Bethencourt F, Fraile B, Onsurbe P, et al. (2006) The p38 transduction pathway in prostatic neoplasia. J Pathol 208: 401-407.
26. Gavrilov D, Kenzior O, Evans M, Calaluce R, Folk WR (2001) Expression of urokinase plasminogen activator and receptor in conjunction with the ets family and AP-1 complex transcription factors in high grade prostate cancers. Eur J Cancer 37: 1033-1040.
27. DeLuca NA, McCarthy AM, Schaffer PA (1985) Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4. J Virol 56: 558-570.
28. Wu N, Watkins SC, Schaffer PA, DeLuca NA (1996) Prolonged gene expression and cell survival after infection by a herpes simplex virus mutant defective in the immediate-early genes encoding ICP4, ICP27, and ICP22. J Virol 70: 6358-6369.